O'Callaghan C J, Krum H, Conway E L, Lam W, Skiba M A, Howes L G, Louis W J
Hypertension Services, Austin Hospital, Melbourne, VIC.
Med J Aust. 1995 Feb 20;162(4):206-8. doi: 10.5694/j.1326-5377.1995.tb126026.x.
To determine the efficacy of pravastatin in the treatment of primary hypercholesterolaemia in patients being treated with captopril for hypertension.
A double-blind parallel group study comparing 12 weeks of pravastatin therapy (20-40 mg/day) with placebo.
25 patients (age, 37-73 years) with mild-to-moderate hypertension and hypercholesterolaemia (total cholesterol level, 5.5-8.8 mmol/L).
Pravastatin reduced total cholesterol levels by 22% (from 7.1 +/- 0.29 [SEM] to 5.5 +/- 0.25 mmol/L; P < 0.001) and low-density-lipoprotein cholesterol levels by 32% (from 5.0 +/- 0.32 to 3.4 +/- 0.28 mmol/L; P < 0.001) in four weeks and these levels were maintained for the 12 weeks of therapy. Pre-pravastatin values returned three weeks after stopping therapy. Levels of total cholesterol, cholesterol fractions and triglycerides remained constant or deteriorated in the placebo group. Pravastatin therapy was well tolerated. An integrated coronary risk score showed a 40% reduction in risk.
This study indicates that pravastatin (combined with captopril) is an effective cholesterol-lowering drug, but that treatment needs to be maintained.
确定普伐他汀对正在接受卡托普利治疗高血压的原发性高胆固醇血症患者的疗效。
一项双盲平行组研究，比较12周的普伐他汀治疗（20 - 40毫克/天）与安慰剂。
25例年龄在37 - 73岁之间的轻度至中度高血压和高胆固醇血症患者（总胆固醇水平为5.5 - 8.8毫摩尔/升）。
普伐他汀在四周内使总胆固醇水平降低了22%（从7.1±0.29[标准误]降至5.5±0.25毫摩尔/升；P<0.001），低密度脂蛋白胆固醇水平降低了32%（从5.0±0.32降至3.4±0.28毫摩尔/升；P<0.001），且在12周治疗期间这些水平得以维持。停止治疗三周后，普伐他汀治疗前的值恢复。安慰剂组的总胆固醇、胆固醇组分和甘油三酯水平保持不变或恶化。普伐他汀治疗耐受性良好。综合冠状动脉风险评分显示风险降低了40%。
本研究表明，普伐他汀（与卡托普利联合使用）是一种有效的降胆固醇药物，但治疗需要持续进行。
